Roth Capital Affirms Pieris Pharma (PIRS) at 'Buy' Following Positive PRS-343 Data

September 27, 2016 10:48 AM EDT
Get Alerts PIRS Hot Sheet
Price: $1.82 +1.68%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 29 | Down: 30 | New: 23
Trade PIRS Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Roth Capital affirms Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) at Buy with a price target of $6 after the company announced that it presented new preclinical data demonstrating in vivo efficacy of its lead 4-1BB (CD137)-based bispecific cancer immunotherapeutic drug candidate, PRS-343.

Analyst Joseph Pantginis commented, We believe that the results presented today are encouraging and that they build a strong data based foundation for the idea that tumor localized co-stimulatory T cell activation by the bispecific PRS-343 may 1) lead to higher efficacy, and 2) result in reduced systemic toxicity relative to an anti-4-1BB mAb. This foundation, which is the basis for the Phase I trial to be initiated in 1H17, in combination with its manufacturing profile, are critical factors that will weigh in for the potential success of PRS-343, in our belief.

For an analyst ratings summary and ratings history on Pieris Pharmaceuticals click here. For more ratings news on Pieris Pharmaceuticals click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Roth Capital, S3

Add Your Comment